ID   CPMD8_HUMAN             Reviewed;        1885 AA.
AC   Q8IZJ3; Q8NC09; Q9ULD7;
DT   05-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   28-JUN-2023, entry version 146.
DE   RecName: Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 {ECO:0000303|PubMed:15177561};
DE   Flags: Precursor;
GN   Name=CPAMD8 {ECO:0000312|HGNC:HGNC:23228};
GN   Synonyms=KIAA1283 {ECO:0000312|EMBL:BAA86597.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION BY MASS
RP   SPECTROMETRY, TISSUE SPECIFICITY, CLEAVAGE BY FURIN-LIKE PROTEASE,
RP   SUBCELLULAR LOCATION, INDUCTION BY IL1B AND IL6, INTERACTION WITH HEPARIN,
RP   AND VARIANTS GLN-294 AND ILE-1268.
RX   PubMed=15177561; DOI=10.1016/j.ygeno.2003.12.005;
RA   Li Z.-F., Wu X.-H., Engvall E.;
RT   "Identification and characterization of CPAMD8, a novel member of the
RT   complement 3/alpha2-macroglobulin family with a C-terminal Kazal domain.";
RL   Genomics 83:1083-1093(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-1885 (ISOFORM 1), AND VARIANTS
RP   GLN-294 AND ILE-1268.
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1479-1885 (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INVOLVEMENT IN ASGD8, AND VARIANT
RP   ASGD8 PRO-1404.
RX   PubMed=27839872; DOI=10.1016/j.ajhg.2016.09.022;
RA   Cheong S.S., Hentschel L., Davidson A.E., Gerrelli D., Davie R., Rizzo R.,
RA   Pontikos N., Plagnol V., Moore A.T., Sowden J.C., Michaelides M., Snead M.,
RA   Tuft S.J., Hardcastle A.J.;
RT   "Mutations in CPAMD8 cause a unique form of autosomal-recessive anterior
RT   segment dysgenesis.";
RL   Am. J. Hum. Genet. 99:1338-1352(2016).
CC   -!- SUBUNIT: Interacts with heparin. {ECO:0000269|PubMed:15177561}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:15177561}. Cell
CC       membrane {ECO:0000269|PubMed:15177561}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:15177561}; Extracellular side
CC       {ECO:0000269|PubMed:15177561}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8IZJ3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IZJ3-2; Sequence=VSP_031137, VSP_031138;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the kidney, brain and testis
CC       and to a lower extent in heart, liver and small intestine
CC       (PubMed:15177561). Expressed in the lens, cornea and retina. Strongly
CC       expressed in the distal tips of the retinal neuroepithelium that form
CC       the iris and ciliary body (PubMed:27839872).
CC       {ECO:0000269|PubMed:15177561, ECO:0000269|PubMed:27839872}.
CC   -!- DEVELOPMENTAL STAGE: Expressed early in development of the eye (week 9
CC       to week 22 of gestation). {ECO:0000269|PubMed:27839872}.
CC   -!- INDUCTION: Up-regulated by IL1B/interleukin-1 beta and IL6/interleukin-
CC       6. {ECO:0000269|PubMed:15177561}.
CC   -!- PTM: Proteolytically cleaved into 2 chains of about 70 and 130 kDa. The
CC       fragments are not connected by disulfide bonds.
CC       {ECO:0000269|PubMed:15177561}.
CC   -!- DISEASE: Anterior segment dysgenesis 8 (ASGD8) [MIM:617319]: A form of
CC       anterior segment dysgenesis, a group of defects affecting anterior
CC       structures of the eye including cornea, iris, lens, trabecular
CC       meshwork, and Schlemm canal. Anterior segment dysgeneses result from
CC       abnormal migration or differentiation of the neural crest derived
CC       mesenchymal cells that give rise to components of the anterior chamber
CC       during eye development. Different anterior segment anomalies may exist
CC       alone or in combination, including iris hypoplasia, enlarged or reduced
CC       corneal diameter, corneal vascularization and opacity, posterior
CC       embryotoxon, corectopia, polycoria, abnormal iridocorneal angle,
CC       ectopia lentis, and anterior synechiae between the iris and posterior
CC       corneal surface. Clinical conditions falling within the phenotypic
CC       spectrum of anterior segment dysgeneses include aniridia, Axenfeld
CC       anomaly, Reiger anomaly/syndrome, Peters anomaly, and
CC       iridogoniodysgenesis. ASGD8 patients predominantly manifest iris and
CC       lens abnormalities, in the absence of retinal abnormalities or extra-
CC       ocular features. ASGD8 transmission pattern is consistent with
CC       autosomal recessive inheritance. {ECO:0000269|PubMed:27839872}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protease inhibitor I39 (alpha-2-
CC       macroglobulin) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11400.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY101765; AAM50084.1; -; mRNA.
DR   EMBL; AC008737; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC020908; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB033109; BAA86597.1; -; mRNA.
DR   EMBL; AK075099; BAC11400.1; ALT_INIT; mRNA.
DR   CCDS; CCDS42519.2; -. [Q8IZJ3-1]
DR   AlphaFoldDB; Q8IZJ3; -.
DR   SMR; Q8IZJ3; -.
DR   BioGRID; 118033; 6.
DR   IntAct; Q8IZJ3; 3.
DR   STRING; 9606.ENSP00000402505; -.
DR   GlyCosmos; Q8IZJ3; 6 sites, 1 glycan.
DR   GlyGen; Q8IZJ3; 6 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8IZJ3; -.
DR   PhosphoSitePlus; Q8IZJ3; -.
DR   SwissPalm; Q8IZJ3; -.
DR   BioMuta; CPAMD8; -.
DR   DMDM; 259016204; -.
DR   EPD; Q8IZJ3; -.
DR   jPOST; Q8IZJ3; -.
DR   MassIVE; Q8IZJ3; -.
DR   PaxDb; Q8IZJ3; -.
DR   PeptideAtlas; Q8IZJ3; -.
DR   ProteomicsDB; 71357; -. [Q8IZJ3-1]
DR   ProteomicsDB; 71358; -. [Q8IZJ3-2]
DR   Antibodypedia; 27470; 38 antibodies from 11 providers.
DR   Ensembl; ENST00000443236.7; ENSP00000402505.3; ENSG00000160111.15. [Q8IZJ3-1]
DR   Ensembl; ENST00000651564.2; ENSP00000498697.2; ENSG00000160111.15. [Q8IZJ3-2]
DR   MANE-Select; ENST00000443236.7; ENSP00000402505.3; NM_015692.5; NP_056507.3.
DR   UCSC; uc002nfb.4; human. [Q8IZJ3-1]
DR   AGR; HGNC:23228; -.
DR   GeneCards; CPAMD8; -.
DR   HGNC; HGNC:23228; CPAMD8.
DR   HPA; ENSG00000160111; Tissue enhanced (brain, prostate, seminal vesicle).
DR   MalaCards; CPAMD8; -.
DR   MIM; 608841; gene.
DR   MIM; 617319; phenotype.
DR   neXtProt; NX_Q8IZJ3; -.
DR   OpenTargets; ENSG00000160111; -.
DR   Orphanet; 519388; Autosomal recessive anterior segment dysgenesis.
DR   PharmGKB; PA134915057; -.
DR   VEuPathDB; HostDB:ENSG00000160111; -.
DR   eggNOG; KOG1366; Eukaryota.
DR   GeneTree; ENSGT00940000162399; -.
DR   HOGENOM; CLU_001634_1_0_1; -.
DR   InParanoid; Q8IZJ3; -.
DR   OrthoDB; 2970602at2759; -.
DR   PhylomeDB; Q8IZJ3; -.
DR   TreeFam; TF313285; -.
DR   PathwayCommons; Q8IZJ3; -.
DR   SignaLink; Q8IZJ3; -.
DR   BioGRID-ORCS; 27151; 132 hits in 1146 CRISPR screens.
DR   ChiTaRS; CPAMD8; human.
DR   GenomeRNAi; 27151; -.
DR   Pharos; Q8IZJ3; Tbio.
DR   PRO; PR:Q8IZJ3; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8IZJ3; protein.
DR   Bgee; ENSG00000160111; Expressed in apex of heart and 156 other tissues.
DR   ExpressionAtlas; Q8IZJ3; baseline and differential.
DR   Genevisible; Q8IZJ3; HS.
DR   GO; GO:0005615; C:extracellular space; IEA:InterPro.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0001654; P:eye development; IMP:UniProtKB.
DR   GO; GO:0010466; P:negative regulation of peptidase activity; IEA:UniProtKB-KW.
DR   CDD; cd02897; A2M_2; 1.
DR   CDD; cd00104; KAZAL_FS; 1.
DR   Gene3D; 1.50.10.20; -; 1.
DR   Gene3D; 2.20.130.20; -; 1.
DR   Gene3D; 2.60.120.1540; -; 1.
DR   Gene3D; 2.60.40.1930; -; 2.
DR   Gene3D; 2.60.40.1940; -; 1.
DR   Gene3D; 3.30.60.30; -; 1.
DR   Gene3D; 6.20.50.160; -; 1.
DR   Gene3D; 2.60.40.690; Alpha-macroglobulin, receptor-binding domain; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 2.
DR   InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR   InterPro; IPR036595; A-macroglobulin_rcpt-bd_sf.
DR   InterPro; IPR011625; A2M_N_BRD.
DR   InterPro; IPR041813; A2M_TED.
DR   InterPro; IPR047565; Alpha-macroglob_thiol-ester_cl.
DR   InterPro; IPR011626; Alpha-macroglobulin_TED.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002350; Kazal_dom.
DR   InterPro; IPR036058; Kazal_dom_sf.
DR   InterPro; IPR001599; Macroglobln_a2.
DR   InterPro; IPR019742; MacrogloblnA2_CS.
DR   InterPro; IPR022041; Methyltransf_FA.
DR   InterPro; IPR002890; MG2.
DR   InterPro; IPR041555; MG3.
DR   InterPro; IPR040839; MG4.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   PANTHER; PTHR11412:SF139; C3 AND PZP-LIKE ALPHA-2-MACROGLOBULIN DOMAIN-CONTAINING PROTEIN 8; 1.
DR   PANTHER; PTHR11412; MACROGLOBULIN / COMPLEMENT; 1.
DR   Pfam; PF00207; A2M; 1.
DR   Pfam; PF07703; A2M_BRD; 1.
DR   Pfam; PF07677; A2M_recep; 1.
DR   Pfam; PF07648; Kazal_2; 1.
DR   Pfam; PF12248; Methyltransf_FA; 1.
DR   Pfam; PF01835; MG2; 1.
DR   Pfam; PF17791; MG3; 1.
DR   Pfam; PF17789; MG4; 1.
DR   Pfam; PF07678; TED_complement; 1.
DR   SMART; SM01360; A2M; 1.
DR   SMART; SM01359; A2M_N_2; 1.
DR   SMART; SM01361; A2M_recep; 1.
DR   SMART; SM00280; KAZAL; 1.
DR   SMART; SM01419; Thiol-ester_cl; 1.
DR   SUPFAM; SSF49410; Alpha-macroglobulin receptor domain; 1.
DR   SUPFAM; SSF81296; E set domains; 1.
DR   SUPFAM; SSF100895; Kazal-type serine protease inhibitors; 1.
DR   SUPFAM; SSF48239; Terpenoid cyclases/Protein prenyltransferases; 1.
DR   PROSITE; PS00477; ALPHA_2_MACROGLOBULIN; 1.
DR   PROSITE; PS51465; KAZAL_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Disease variant; Disulfide bond;
KW   Glycoprotein; Membrane; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..1885
FT                   /note="C3 and PZP-like alpha-2-macroglobulin domain-
FT                   containing protein 8"
FT                   /id="PRO_0000317695"
FT   DOMAIN          1706..1757
FT                   /note="Kazal-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   REGION          1514..1548
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1793..1852
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1818..1836
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            671..672
FT                   /note="Cleavage; by furin-like protease"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        117
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        190
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        267
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        757
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1439
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        1712..1742
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        1716..1735
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        1724..1755
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   VAR_SEQ         1809..1815
FT                   /note="RVTAGPR -> SQSGFSS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_031137"
FT   VAR_SEQ         1816..1885
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_031138"
FT   VARIANT         251
FT                   /note="R -> W (in dbSNP:rs10426545)"
FT                   /id="VAR_038655"
FT   VARIANT         265
FT                   /note="M -> T (in dbSNP:rs4808551)"
FT                   /id="VAR_038656"
FT   VARIANT         294
FT                   /note="R -> Q (in dbSNP:rs3745340)"
FT                   /evidence="ECO:0000269|PubMed:10574462,
FT                   ECO:0000269|PubMed:15177561"
FT                   /id="VAR_038657"
FT   VARIANT         539
FT                   /note="D -> E (in dbSNP:rs3745335)"
FT                   /id="VAR_038658"
FT   VARIANT         546
FT                   /note="H -> R (in dbSNP:rs1824152)"
FT                   /id="VAR_038659"
FT   VARIANT         736
FT                   /note="P -> H (in dbSNP:rs9305083)"
FT                   /id="VAR_038660"
FT   VARIANT         1156
FT                   /note="V -> I (in dbSNP:rs2250918)"
FT                   /id="VAR_038661"
FT   VARIANT         1268
FT                   /note="T -> I (in dbSNP:rs706761)"
FT                   /evidence="ECO:0000269|PubMed:10574462,
FT                   ECO:0000269|PubMed:15177561"
FT                   /id="VAR_038662"
FT   VARIANT         1404
FT                   /note="S -> P (in ASGD8; dbSNP:rs1057519340)"
FT                   /evidence="ECO:0000269|PubMed:27839872"
FT                   /id="VAR_077933"
FT   VARIANT         1843
FT                   /note="Q -> R (in dbSNP:rs1054533)"
FT                   /id="VAR_038663"
FT   CONFLICT        1588
FT                   /note="S -> G (in Ref. 4; BAC11400)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1885 AA;  206702 MW;  5AA522DE6155C288 CRC64;
     MSGALLWPLL PLLLLLLSAR DGVRAAQPQA PGYLIAAPSV FRAGVEEVIS VTIFNSPREV
     TVQAQLVAQG EPVVQSQGAI LDKGTIKLKV PTGLRGQALL KVWGRGWQAE EGPLFHNQTS
     VTVDGRGASV FIQTDKPVYR PQHRVLISIF TVSPNLRPVN EKLEAYILDP RGSRMIEWRH
     LKPFCCGITN MSFPLSDQPV LGEWFIFVEM QGHAYNKSFE VQKYVLPKFE LLIDPPRYIQ
     DLDACETGTV RARYTFGKPV AGALMINMTV NGVGYYSHEV GRPVLRTTKI LGSRDFDICV
     RDMIPADVPE HFRGRVSIWA MVTSVDGSQQ VAFDDSTPVQ RQLVDIRYSK DTRKQFKPGL
     AYVGKVELSY PDGSPAEGVT VQIKAELTPK DNIYTSEVVS QRGLVGFEIP SIPTSAQHVW
     LETKVMALNG KPVGAQYLPS YLSLGSWYSP SQCYLQLQPP SHPLQVGEEA YFSVKSTCPC
     NFTLYYEVAA RGNIVLSGQQ PAHTTQQRSK RAAPALEKPI RLTHLSETEP PPAPEAEVDV
     CVTSLHLAVT PSMVPLGRLL VFYVRENGEG VADSLQFAVE TFFENQVSVT YSANETQPGE
     VVDLRIRAAR GSCVCVAAVD KSVYLLRSGF RLTPAQVFQE LEDYDVSDSF GVSREDGPFW
     WAGLTAQRRR RSSVFPWPWG ITKDSGFAFT ETGLVVMTDR VSLNHRQDGG LYTDEAVPAF
     QPHTGSLVAV APSRHPPRTE KRKRTFFPET WIWHCLNISD PSGEGTLSVK VPDSITSWVG
     EAVALSTSQG LGIAEPSLLK TFKPFFVDFM LPALIIRGEQ VKIPLSVYNY MGTCAEVYMK
     LSVPKGIQFV GHPGKRHVTK KMCVAPGEAE PIWVVLSFSD LGLNNITAKA LAYGDTNCCR
     DGRSSKHPEE NHADRRVPIG VDHVRRSVMV EAEGVPRAYT YSAFFCPSER VHISTPNKYE
     FQYVQRPLRL TRFDVAVRAH NDARVALSSG PQDTAGMIEI VLGGHQNTRS WISTSKMGEP
     VASAHTAKIL SWDEFRTFWI SWRGGLIQVG HGPEPSNESV IVAWTLPRPP EVQFIGFSTG
     WGSMGEFRIW RKMEVDESYS EAFTLGVPHG AIPGSERATA SIIGDVMGPT LNHLNNLLRL
     PFGCGEQNMI HFAPNVFVLK YLQKTQQLSP EVERETTDYL VQGYQRQLTY KRQDGSYSAF
     GERDASGSMW LTAFVLKSFA QARSFIFVDP RELAAAKSWI IQQQQADGSF LAVGRVLNKD
     IQGGIHGTVP LTAYVVVALL ETGTASEEER GSTDKARHFL ESAAPLAMDP YSCALTTYAL
     TLLRSPAAPE ALRKLRSLAI MRDGVTHWSL SNSWDVDKGT FLSFSDRVSQ SVVSAEVEMT
     AYALLTYTLL GDVAAALPVV KWLSQQRNAL GGFSSTQDTC VALQALAEYA ILSYAGGINL
     TVSLASTNLD YQETFELHRT NQKVLQTAAI PSLPTGLFVS AKGDGCCLMQ IDVTYNVPDP
     VAKPAFQLLV SLQEPEAQGR PPPMPASAAE GSRGDWPPAD DDDPAADQHH QEYKVMLEVC
     TRWLHAGSSN MAVLEVPLLS GFRADIESLE QLLLDKHMGM KRYEVAGRRV LFYFDEIPSR
     CLTCVRFRAL RECVVGRTSA LPVSVYDYYE PAFEATRFYN VSTHSPLARE LCAGPACNEV
     ERAPARGPGW FPGESGPAVA PEEGAAIARC GCDHDCGAQG NPVCGSDGVV YASACRLREA
     ACRQAAPLEP APPSCCALEQ RLPASSSSTY GDDLASVAPG PLQQDVKLNG AGLEVEDSDP
     EPEGEAEDRV TAGPRPPVSS GNLESSTQSA SPFHRWGQTP APQRHSGRVV GAHRPGLLSP
     VFVYSPAFQS GGEEGLWMSN TCTLR
//
